InsidersTradesSigma
Follow the PHARVARIS N V share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.4bn. The latest transaction was reported on 14 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Berndt B.A,E. Modig. The full history is accessible without an account.
Analysts rate PHARVARIS N V Strong Buy (bullish), based on 14 analysts. Average price target: US$49.29.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
PHARVARIS N V is a company focused on developing treatments for rare diseases, particularly those related to histamine disorders. It is listed on NASDAQ.